Thomas Winkler, MD

VP, Clinical Development
Fulcrum Therapeutics
Cambridge, Massachusetts, United States

Presentation(s):

• A Phase 1b, Open-Label, Multiple-Dose Study Evaluating Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Pociredir in Patients with Sickle Cell Disease (SCD): Trial Design

  Saturday, June 7, 2025
  8:40 AM - 9:00 AM ET